Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 3% self-developed RC148 to achieve dual path breakthrough, institutions are optimistic about subsequent clinical potential

The Zhitong Finance App learned that Rongchang Biotech (09995) rose more than 3%. As of press release, it had risen 3.41% to HK$78.8, with a turnover of HK$98.3812 million.

According to the news, the Huaxi Securities Research Report pointed out that according to Rongchang Biotech's official account, the company's self-developed PD-1/VEGF bispecific antibody RC148 single-agent first-line and second-line treatment of non-small cell lung cancer phase I/II clinical data was announced. Research data showed that both the RC148 single drug and the combined regimen showed outstanding clinical efficacy and controllable safety, and achieved a dual-path breakthrough.

According to the bank, based on early data from the RC148-C001 study, in August 2025, RC148 combined with docetaxel for treating drivergene-negative locally advanced or metastatic non-small cell lung cancer that failed treatment with PD-1/PD-L1 inhibitors and platinum-containing chemotherapy (combination or sequential) had obtained breakthrough therapeutic drug qualification (BTD) in China. Currently, the company is actively promoting related clinical trials: According to the company's investor research records, the phase II clinical trial of RC148 combined treatment for first-line non-small cell lung cancer has completed patient enrollment and plans to start a phase III clinical study of combined treatment for non-small cell lung cancer, and is optimistic about subsequent clinical potential.